Roth Capital Downgrades Synta Pharma. (SNTA) to Neutral; $1 PT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
JMP Securities Downgrades Synta Pharma. (SNTA) to Market Perform
October 21, 2015 2:11 PM EDTJMP Securities downgraded Synta Pharma. (NASDAQ: SNTA) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $2.04 yesterday.
... MoreCowen Downgrades Synta Pharma. (SNTA) to Market Perform
October 21, 2015 2:01 PM EDTCowen downgraded Synta Pharma. (NASDAQ: SNTA) from Outperform to Market Perform.
Analyst Boris Peaker commented, "In light of GALAXY-2's stoppage, we are downgrading shares of SNTA from Outperform to Market Perform without a price target. In our view there are limited... More
FBR Capital Downgrades Synta Pharma. (SNTA) to Market Perform Amid GALAXY-2 Termination
October 21, 2015 12:28 PM EDTFBR Capital downgraded Synta Pharma. (NASDAQ: SNTA) from Outperform to Market Perform and cuts its price target from $6 to $2.
Analyst Christopher James noted the following:
No separation of the curves following interim analysis. Following the termination of GALAXY-2, we do not see a clear path forward for ganetespib. Since the remaining studies with ganetespib are... MoreSynta Pharma (SNTA) Terminates Phase 3 GALAXY-2 Trial in Lung Cancer Due to Futility
October 21, 2015 7:25 AM EDTSynta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the studys Independent Data Monitoring Committee (IDMC) concluded that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel alone. The IDMC noted... More
